Immune Checkpoint Inhibitor-Related Sjögren’s Syndrome: An Ocular Immune-Related Adverse Event
A 67-year-old male with metastatic human papillomavirus (HPV)-positive oropharyngeal cancer receiving pembrolizumab (anti-programmed cell death protein 1 [PD-1] immune checkpoint inhibitor) presented with bilateral ocular dryness. It is important to note that these symptoms appeared eight months aft...
Saved in:
| Main Authors: | Hideki Fukuoka, Akifumi Matsumoto, Chie Sotozono |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/9/1168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging Trends and Management for Sjögren Syndrome-Related Dry Eye Corneal Alterations
by: Maria Letizia Salvetat, et al.
Published: (2025-05-01) -
A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
by: Le Xu, et al.
Published: (2025-12-01) -
Late-onset bone granulomatous reaction of hand from immune checkpoint-inhibitors detected on FDG-PET/CT
by: Miki Nishimori, et al.
Published: (2025-05-01) -
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
by: Tianhang Zhang, et al.
Published: (2024-12-01) -
Ocular Manifestations of Perinatal HIV Infection in Kenyan Children on HAART: A Cross-Sectional Comparative Study
by: Alisi L, et al.
Published: (2025-07-01)